TAIPEI, Taiwan – The global biotech market is in a period of low productivity, high costs and less-than-ideal levels of efficiency. Such conditions are pushing pharmaceutical firms in the Asia-Pacific region to develop creative strategies that often require looking elsewhere for innovative solutions and products.